Method for preventing and treating colitis in excluded colon

FIELD: medicine.

SUBSTANCE: 0.5% dihydroquercetin is instilled into the rectum of a patient with temporary colostomy until he/she starts feeling intestinal inflation. The procedure is performed twice a day, daily up until the restorative surgery.

EFFECT: method reduces a rate and a degree of colitis manifestations by the local antioxidant, anti-inflammatory effect, unfolding the excluded colon.

 

The invention relates to medicine, in particular to surgery, and can be used for the treatment and prevention of colitis disabled colon.

In some cases the operation is performed on the colon could not be completed restoration of the continuity of the intestinal tube in one step, and requires the operation overlay colostomy discharge with subsequent reconstructive intervention. However, according to the literature, 23.7% of cases may develop a variety of complications reconstructive surgery due to the development of the patient's inflammatory process in the colon distal to the stoma, so-called "colitis disabled colon" (kotc), which develops in 70% of ostomy patients [2, 7]. In addition, according to some authors, in the case of the described syndrome marked decrease in the maximum carrying capacity of the content is disabled rectum with 157 to 87 ml 3 months after cutoff when the length of the stump to 22 cm, due to the involutive changes stump colon[7, 8, 10, 11]. This, in turn, leads to deterioration of the function of the colon after reconstructive surgery and, as a result, deterioration in the quality of life of patients.

The mechanism of development of inflammatory processes in the disabled divisions of large Ki�Ki can be corregirian by applying different in nature and mechanism of action of drugs.

Thus, the known method of correcting kotc through the use of products containing short-chain fatty acids [2]. However, S. Neut et al. (1997) in her study had not received a positive result from treatment with drugs of this group [9].

Proposed treatments kotc the introduction into the rectum of chamomile extract [4]. However, the effect of this treatment has not been studied with modern evidence-based medicine.

Also for the treatment of kotc applied corticosteroids and 5-aminosalicylic acid. However, some authors point to the lack of effect of treatment and even the progression of a disease with the use of steroid drugs, and the use of drugs 5-aminosalicylic acid is relevant only in case of development of severe forms of colitis [2]. The use of drugs 5-aminosalicylic acid to prevent the development of this syndrome is not carried out in view of a number of possible unwanted effects.

The object of the invention is to provide a method of correction colitis disabled intestine, through the use of local anti-inflammatory effect of the drug introduced into the lumen of the disabled intestine.

A method of correction colitis disabled colon using a solution of an antioxidant of plant origin of dihydroquercetin (DHA). Use �Reparata plant origin with antioxidant and anti-inflammatory effect prognostically will be preferred and effective in the prevention and treatment of this syndrome in monotherapy, or in combination with other methods of correction.

The essence of the invention consists in the use of standard treatment for patients with temporary colostomy 0.5% solution of DHA, which is instilled into the rectum until the feeling of filling of the gut twice a day every day until reconstructive surgery.

According to the literature DHA has anti-inflammatory, antioxidant, wound healing, anti-tumor effect[1, 3, 5, 6].

There is information about the effectiveness of 0.5% solution of DHA in complex conservative treatment of chronic tonsillitis and sinusitis [1, 6]; in the treatment of wounds in patients operated on for mastitis [3]. Last used as a prototype. The essence of this method consists of washing the wound with 0.5% solution of DHA.

Method of prevention and treatment kotc with dihydroquercetin previously described.

The task is achieved through the use of a 0.5% solution of dihydroquercetin in developed and aprobirovanie in the clinic the way effectively to prevent and to correct kotc in the case of its development.

The method is as follows.

As part of the standard treatment of patients operated on the colon with the formation of a temporary colostomy, prescribed instillation in PR�needful gut 0.5% solution of dihydroquercetin to the emergence of a sense of filling twice a day every day until reconstructive surgery.

Performed clinical testing of the proposed method.

Studied 20 patients operated in the operation volume Hartmann forming a temporary colostomy. The main group included 10 patients who underwent prevention of kotc by the proposed method. The control group included 10 patients, not statistically different from the main group by age who underwent standard maintenance program ostomy patients without the use of DHA. Patients subsequently conducted reconstructive surgery 3-6 months after the first operation. For monitoring the treatment was applied clinical and instrumental methods of control. To clinical methods were: patient survey, using questionnaires to assess the degree of anorectal dysfunction, quality of life, V. I. estimation of balance (2010), quality of life, SF-36. To instrumental research treated by endoscopic methods - sigmoidoscopy and colonoscopy. The result of applying the proposed method of correction kotc were statistically-significant decrease in the degree of anorectal dysfunction and endoscopic picture of colitis in patients of the main group that has improved the quality of their lives.

As can be seen from the foregoing, the appointment of the patients operated on thick�th intestine with the formation of a temporary colostomy, instillation into the rectum of a 0.5% solution of DHA twice a day until reconstructive surgery, reduces the severity of endoscopic and clinical colitis and improve the quality of life of patients. This method can be applied in a rehabilitation program.

Thus, our proposed method differs from the prototype as in the method of implementation (instillation of 0.5% solution of DHA in the rectum twice a day until the feeling of filling daily until reconstructive surgery), and technical result - prevention and treatment of colitis disabled intestine in patients operated on the colon with the formation of a temporary colostomy.

The technical result of our proposed method is to reduce the incidence of and severity of colitis disabled the colon of the ostomy patients.

The list of references

1. Antipenko Vladimir Conservative and surgical treatment of chronic nonspecific tonsillitis: author. dis. Cand. med. Sciences/ Vladimir Antipenko. - Blagoveshchensk. - 2008. - 18 S.

2. Vorob'ev, G. I. Colitis disabled colon (literature Review) / G. I. Vorobyov, A. P. Zhuchenko, A. F. Philo et al. // RIGHT. - 2008. - No. 5. - P. 65-70.

3. Duplij N. And. Surgical and comprehensive treatment of mastitis with the use of antioxidants: Aut�Ref. dis. Cand. med. Sciences /N. And. Duplij. - Blagoveshchensk. - 2012. - 24 p.

4. Kitsieva G. M. Preparation of disconnected segments of the colon to reconstructive operations: author. dis. Cand. med. Sciences /G. M. Kitsieva. - Moscow. - 2011. - 25 S.

5. Uminski A. Biochemistry of flavonoids and their application in medicine /AA uminski, E. H. Asteep, V. F. Bakanev // Pushchino, 2007. - 257 p.

6. Shmelev, N. In. Conservative and surgical treatment of chronic nonspecific tonsillitis: author. dis. Cand. med. Sciences /N. In. Shmelev. - Saint-Petersburg.- 2008. - 18 S.

7. Jovett S. L. Diversion colitis as a trigger for ulcerative colitis /S. L. Jovett, I. Cobden // Gut. 2000; 46(2):294.

8. Lechner G. L. Lymphoid follicular hyperplasia excluded in colonic segments: a radiologic sign of diversion colitis / G. L. Lechner, Frank W., H. Jantsch et al. // Radiology. -1990. Vol. 176. N 1. - P. 135-136.

9. Neut S. Nitrate-reducing bacteria in diversion colitis: a clue to inflammation / C. Neut, F. Guillemot, J. F. Colombel // Dig. Dis. Sci. - 1997. - Vol. 42, No. 12. - P. 2577-2580.

10. Roe A. M. Diversion colitis and involution of the defunctioned anorectum / A. M. Roe, B. F. Warren, A. J. Brodribb et al. // Gut. - 1993. - Vol.34. - No. 3. - P. 382-385.

11. Warren B. F. Pathology of the defunctioned rectum in ulcerative colitis / B. F. Warren, N. A. Shepherd, C. D. Bartolo et al. // Gut. - 1993. - Vol. 34, N 4. - P. 514-516.

Method for the prevention and treatment of colitis disabled the colon, including the use of a 0.5% solution of dihydroquercetin, characterized in that the composition of the standard treatment for patients with temporary colostomy appoint instillation of a solution into the rectum until the feeling of filling quiche�and twice a day every day until reconstructive surgery.



 

Same patents:

FIELD: medicine.

SUBSTANCE: ozone-oxygen mixture is administered from both sides of a retroperitoneal space into paranephric fat in an amount of up to 500 mg included from each side. The ozone concentration makes 10 mg/l and less. The therapeutic course makes 5-10 sessions every 1-3 days.

EFFECT: effective treatment of the given pathology by supplying the ozone-oxygen mixture directly to an arterial trunk that causes its targeted action.

3 ex

FIELD: medicine.

SUBSTANCE: frontal sinus is approached in a typical location and sanitated. After the sanitation procedure, a bone defect is covered with high-structure hydrogel matrix of sodium alginate, wherein dioxidin 0.03g and ε-aminocapronic acid 0.15g are pre-administered. The sinus is obliterated with MK-9M osteoplastic composition. The approach point is covered with the same matrix, on the top of which the wound is closed completely and coated with Coletex-ADL hydrogel tissue.

EFFECT: method provides preventing early and late suppurative complications, promotes preventing intracranial complications, reduces the recovery time by the protective antiseptic, homeostatic, antitoxic properties of the used matrix, which prevents the composition prolapse into the intracranial cavity as a brace.

4 dwg, 2 ex

FIELD: medicine.

SUBSTANCE: patients keep a diet with reducing an amount of liquid taken up to 1.5l a day that is compensated by the intravenous administration of solutions an amount and composition of which depends on a degree of water-electrolyte disturbances. Additionally, after bandage removal, the wound and edges of the fistulous passage is 5% potassium permanganate, which is then washed with 3% hydrogen peroxide. A mouth of the fistula and the wound edges are dried. That is followed by an aeration of the mouth of the fistula with a cooled plasma flow of nitrogen monoxide at a depth of 0.5cm in the therapeutic mode of 2000 mg/m3 and exposition of 1.5min. The mouth of the fistula and the wound edges are treated with a plasma flow of nitrogen monoxide in the concentration within the contact area with the wound surface of 1500 mg/m3 and time of exposure of 20 seconds per each 1 cm2 of the surface. The mouth of the fistula and the wound edges are dried. The mouth is packed with the gauze swab. The fistulous wound is exposed to EHF waves with the pure noise spectrum and the provided integral power on the wound surface of 1.5 mcWt along the perimeter of the mouth at 15mm from the fistulous passage for 30 minutes. The swab is removed. The mouth and the surrounding skin is treated with zinc paste and covered with gauze swabs. The further bandages are performed in the similar way as the bandage wets with the intestinal contents, but no more than 2 times a day and at least once every 3 days.

EFFECT: safe and effective conservative treatment of the intestinal fistulas at any phase of the wound process that enables avoiding risks of surgical intervention and general anaesthesia by rapid reduction of skin maceration and perifocal inflammation surrounding the mouth and prevents them, stimulates the growths of granulocyte tissue and epithelisation of the fistuous wound.

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to thoracic surgery, and can be used to close defects of the lower one-third of the oesophagus. A laparotomy and a sagittal diaphragmotomy are performed. The oesophageal wall defect is closed with a single-layer uninterrupted absorbable mass suture. The suture is started from the proximal end of the defect with the first knot tightened into the oesophageal lumen. A fundoplication cuff is created with covering the suture with the stomach. One of the gastric walls is fixed by interrupted sutures surrounding the closed oesophageal defect to form a cavity between the closed oesophageal defect and the gastric wall. The cavity is filled with Coletex ADL hydrogel tissue. The fundoplication cuff is fixed by interrupted sutures circularly to the diaphragm. The pleural spaces, mediastinal and subphrenic space are drained.

EFFECT: method provides reducing the time of recovery, reducing a probability of postoperative complications and faster rehabilitation by forming the reliable sutures, long bactericidal effect on the suture area, dividing the pleural space and abdominal cavity.

1 ex

FIELD: medicine.

SUBSTANCE: endoresection of an intraocular new growth is followed by covering the scleral bed surface with a photosensitising gel (PS gel) containing 0.1% monoethylene diamine monoamide chlorine adipate e6. The PS gel exposure makes 3 minutes. Thereafter, the scleral bed is exposed to laser light at a wave length of 662 nm, light dense of 60 J/cm2, with the fields of 4 mm in diameter in an air medium with the exposure covering the 1.5 mm surrounding tissues. The exposure is circle-wise from the periphery to the centre and covers the adjoining fields by 5% of the area.

EFFECT: avoiding the tumour cells remained viable on the scleral bed after the endoresection of the intraocular new growth, eliminating recurrences of tumours and metastases in the remote postoperative period.

1 ex

FIELD: medicine.

SUBSTANCE: endoresection of an intraocular new growth is followed by covering the scleral bed surface with a photosensitising gel (PS gel) containing 0.1% monoethylene diamine monoamide chlorine adipate e6. The PS gel exposure makes 3 minutes. The residual gel is taken off. An active portion of one needle electrode is intraocularly applied on the scleral bed in parallel with the retinotomy border at 0.5-0.7 mm. The second electrode is applied in parallel to the first one at 3-4 mm to the centre of the scleral bed. That is followed by performing an electrochemical lysis (ECL) at the current intensity of 5 mA for 10 seconds. The electrodes are gradually moved along the scleral bed surface first circle-wise, in parallel to the retinotomy border, then from the periphery to the centre. The ECL covers the entire area of the scleral bed at the current intensity of 5 mA for 10-15 seconds in each position of the electrodes. That is followed by intraocular photodynamic therapy (PDT) along the entire area of the scleral bed with involving the 1.5 mm surrounding tissues. The patient is exposed to laser light at a wave length of 662 nm, power density of 60 J/cm2, by fields of 4 mm in diameter, circle-wise from the periphery to the centre, and involving the adjoining fields by 5% of the area.

EFFECT: avoiding the tumour cells remained viable on the scleral bed after the endoresection of the intraocular new growth, eliminating recurrences of tumours and metastases in the remote postoperative period.

1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to vascular surgery and concerns treating vascular dysplasia. That is ensured by a contrast phlebography of an angiodysplastic lesion by a percutaneous administration of 76% urografin heated to 36.4-37.6°C. That is followed by administering a sclerosing preparation an amount of which (Vsc) is calculated empirically by derived formula Vsc=Vug·0.8, wherein Vug is an amoung of urografin required for visualising a vascular pattern of angiodysplasia. Further, a finger compression of angiodysplasia is performed for at least three minutes.

EFFECT: method enables calculating precisely the required and adequate amount of the sclerosing preparation that provides the effective treatment of angiodysplasia, including difficult ones with minimum side effects.

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to surgery. A polyethylene tube is inserted into a mesentery. A solution containing proserine in a dose of up to 50 mg is introduced through the inserted tube. A synovial fluid 2 ml dissolved in normal saline 10 ml is additionally administered along the enteroenteroanastomosis.

EFFECT: method provides preventing peritoneal adhesions following the abdominal surgical operation by administering the preparations promoting better peristalsis and slide of the intestinal loop in the abdominal cavity.

1 tbl

FIELD: medicine.

SUBSTANCE: upon completion of the surgical intervention, before the abdominal wall closure, microirrigators are inserted through counteropenings into the hypochondria. An end of the right microirrigator is fixed with an interrupted catgut suture to a stump of the resected stomach; an end of the left microirrigator is fixed at an upper level of the abdominal cavity with the interrupted catgut suture. Drain tubes are inserted through the counteropenings in the iliac regions into the small pelvis. The surgical intervention is terminated with treating the whole abdominal cavity with 50 ml ozonised normal saline 1000 mcg/l. Then 10 minutes later, the abdominal cavity is treated with metronidazole 100 ml. From the 1st to 5th postoperative day, metronidazole 200 ml is administered in the form of 24-hour infusion through a portable infusion device via the right microirrigator. Through the left microirrigator, 50 ml ozonised normal saline 1000 mcg/l is administered once a day. A course of standard intravenous antibiotic therapy is prescribed into the patient.

EFFECT: reducing an incidence rate of postoperative infectious-inflammatory complications in the given category of patients due to the specific regimen of the antibacterial therapy and the ozone therapy.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to surgery and can be used in treating lymphorrhea following femoroinguinal lymphadenectomy for skin melanoma. Polysorb MP sterile powder is insufflated into the prepared postoperative wound cavity in the wound edge diastasis. The powder is spread with a dry gauze swab along the whole surface of the wound pocket. That is followed by tight wound tamponade. As the dressing is soaked, Polysorb MP is completely evacuated, and the other dressing is applied until lymphorrhea is terminated.

EFFECT: method provides terminating lymphorrhea in the given category of patients by generating the complexes of silicone oxide and tissue liquid proteins, which create an occlusion of lymphatic vessels lumen.

2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to cosmetic industry and represents a cosmetic product which has the following composition in each specific case calculated using the total composition: at least 0.1 wt % of at least one hydrophilic softening product, 2 to 40 wt % of at least one surfactant specified in a group of fatty alcohol ethoxylates, fatty alcohol ether sulphates and salts of sulphated and/or sulphonated fatty acids, 30 to 90 wt % of water, 1 to 30 wt % of one or more abrasives with the total ingredients making 10%; the product contains at least 0.1 wt % of at least one hydrophilic softening product with a hydrophilic-lipophilic balance ≥8 and flour thermally treated by saturated vapour; the flour is natural flour of shell or kernels characterized by a light absorption at wave length 660 nm of less than 1 prepared by reacting the flour 1 g with a solution prepared of water 10 ml and 0.1% aqueous methylene blue 1 ml.

EFFECT: invention provides the lower effect on viscosity, possesses the high cleaning action and high tolerability.

16 cl, 5 ex, 3 tbl

Foaming detergent // 2543713

FIELD: chemistry.

SUBSTANCE: invention relates to aqueous foaming composition for hands, containing castor oil maleate in amount from 0.1 to 1% of composition weight, PEG-7 glyceryl cocoate in amount from 0.05 to 0.3% of composition weight, glycerol in amount from 0.5 to 6% of composition weight, PEG-6 of glycerides of caprylic/capric acid in amount from 0.05 to 1% of composition weight and SAS. Glycerol is present in amount greater than amount of castor oil maleate or glyceryl cocoate PEG-7, and said composition has viscosity from 1 to 100 mPa·s (sP).

EFFECT: obtaining aqueous foaming composition for hands, which is capable of providing foam stability, has lower tendency for flowing and soiling when applied and creates more pleasant sensations for skin.

7 cl

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to oral care compositions containing a basic amino acid or its salt. The presented oral care composition promoting the dentine defect closure in the oral cavity contains arginine in the free form or in the form of a salt, and an abrasive substance representing synthetic amorphous silica and containing small particle fractures making at least approximately 5% of total weight of the composition, wherein the particles of the small particle fracture having d50 from 3 to 4 mcm. What is also presented is a method of treating sensitive teeth in the oral cavity involving using the oral treatment with this composition, as well as using arginine as a part of the oral care composition and for producing a therapeutic agent, wherein the above composition and agent contain the above abrasive material containing the small particle fracture.

EFFECT: group of inventions provide the effective dentin defect closure in the patient's oral cavity.

8 cl, 1 tbl, 6 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a method of producing technetium-99m labelled nanocolloid for radionuclide diagnosis. The disclosed method includes preparing a starting suspension of a nanocolloid in 0.1% sodium dodecylbenzene sulphate and passing said suspension through a filter with pore diameter of 100 nm, adding a technetium-99m eluate, then adding 0.20-0.25 mg ascorbic acid, 2.5-4.0 mg gelatine and 0.02-0.03 mg tin (II) chloride dihydrate per 1 ml of the mixture. The obtained mixture is heated in a water bath at 70-80°C for 30 minutes, cooled to room temperature in an ultrasonic bath and then subjected to sterilisation filtration. The nanocolloid used is iron-carbon particles whose surface is chemically modified with arenediazonium tosylate.

EFFECT: invention enables to obtain technetium-99m labelled nanocolloid, for which not less than 80% of particles have a size in the range of 20-100 nm, relative content of particles with a size smaller than 20 nm is not more than 6% and radiochemical purity is higher than 90% and is maintained for not less than 4 hours.

1 dwg, 4 ex

FIELD: medicine.

SUBSTANCE: rejuvenating effect is ensured by exposing high-molecular hyaluronic acid to gamma-radiation to preparing a stable low-molecular hyaluronic acid, which is used as a prescribed ingredient alongside with synthesised matrix peptide of specific amino acid sequence.

EFFECT: prescribed combination of low-molecular hyaluronic acid and matrix peptides of the developed cosmetic product enables achieving the pronounced aesthetic effect by a physiological mechanism of stimulation of developing proper hyaluronic acid in the skin.

2 dwg, 1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical industry and represents an oral care composition, which contains 5 - 95 wt % of an orally acceptable carrier; and a film, wherein the above film contains 10 - 60 wt % of the film of an odour control active ingredient (a zinc-containing compound), 2 - 5 wt % of the film of a mucoadhesive polymer (polyacrylic acid or polyacrylate, polyalkylacrylate, polyvinylpyrrolidone, poly(acrylate)/polyvinylpyrrolidone copolymer, chitosan, 20 - 30 wt % of the film of one or more release controlling polymers (polyvinyl acetate or hydroxyethyl cellulose), 25 - 50 wt % of the film of a polymeric base (hydroxypropyl methyl cellulose, methyl cellulose, hydroxypropyl cellulose and a copolymer thereof) and a flavouring agent, wherein the above film is integrated into the above orally acceptable carrier and makes 0.1 - 5 wt % of the orally acceptable carrier.

EFFECT: invention provides creating the agent able to keep the breath fresh for a long period of time.

5 cl, 5 ex, 7 tbl, 6 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical industry and represents a foaming personal care composition containing: - a carrier; - an oil phase containing at least one terpene alcohol, which has a cyclic structure; - at least partially fluorinated compound; and - a stabilising agent, wherein the mass ratio of at least partially fluorinated compound and terpene alcohol makes from 2:1 to 4:1.

EFFECT: composition possesses higher stability and provides initial foaming and a longer positive skin effects, including cleansing and moistening.

16 cl, 12 tbl, 14 ex

Dry face mask // 2543355

FIELD: chemistry.

SUBSTANCE: invention represents a dry face mask containing a base, ground natural biologically active crude drugs, a natural abrasive, wherein the base is fermented malt, while the natural abrasive is ground dry rice having a particle size of 50-100 mcm; the mask ingredients are taken in certain relation, wt %.

EFFECT: invention enables reducing a possibility of skin injuries, promotes dynamic and age-related rhytid effacement, relieving skin inflammations and eliminating pigment spots.

4 cl, 6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to chemotherapy of cancer and represents a composition for hepatic cancer in individuals and containing a complex of formula [M(RCS3)2(RCS2)], wherein M represents 188Re having an activity of more than 3.7 GBq and a lipophilic organic phase emulsified with a water phase; as well as a method for preparing the above composition.

EFFECT: invention provides higher stability and efficacy of the composition for treating hepatic cancer in the individuals.

17 cl, 1 dwg, 9 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the pharmaceutical industry, particularly to a composition for treating or preventing the human immunodeficiency virus (HIV) or hepatitis C. The herbal composition used for treating or preventing the patients infected by the HIV or hepatitis C viruses and containing a herbal ingredient with tannin agents and catechin, and a pharmaceutically acceptable carrier; the herbal ingredient is Agrimonia Eupatoria (GAFT) and/or gambier (Uncaria gambir). A method for preparing the herbal composition for treating or preventing the patients infected by the HIV or hepatitis C viruses.

EFFECT: composition is effective for treating or preventing the patients infected by the HIV or hepatitis C viruses.

12 cl, 6 dwg, 2 tbl

FIELD: medicine.

SUBSTANCE: method involves forming an artificial symphalangia, measuring a defect area, forming an axial fascial flap of the forearm, fixing it to the involved distal fingers, covering the flap with a split skin graft. The artificial symphalangias are formed with fixing full-thickness skin grafts in interfinger spaces; the pedicle is covered with the split skin graft by wrapping, leaving it free.

EFFECT: method reduces the length of treatment, improves the clinical outcomes by forming the artificial symphalangias, creating a combined wound surface, separating the symphalangias with forming no defects on the side surfaces on the fingers.

1 ex, 4 dwg

Up!